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31 Abstract
2 Background 
3 Patients with mutations of succinate dehydrogenase B (SDHB) and D (SDHD) 
4 are at high risk of paraganglioma (PGL) necessitating surveillance. 
5 Chromogranin A (CgA) has been proposed as a biochemical marker of PGL. We 
6 sought to determine the diagnostic utility of CgA in a population based SDHx 
7 sample.
8
9 Methods
10 Tasmania is an island state with one tertiary referral centre for endocrine 
11 neoplasia. We performed cross sectional analysis of all adult SDHB (n=52) and 
12 SDHD (n=10) patients undergoing PGL surveillance between 2011 and 2017. 
13 CgA was referenced against the outcome of PGL surveillance with a minimum of 
14 18F-fluorodeoxyglucose positron emission tomography/computed tomography 
15 (18F-FDG PET/CT) and plasma metanephrines (metanephrine and 
16 normetanephrine).
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2 Results 
3 CgA correctly predicted the result of PGL surveillance more often in patients with 
4 SDHB compared to those with SDHD (77% vs 22%, p=0.003). In the SDHB 
5 group, CgA demonstrated a sensitivity of 67% and specificity of 79% compared 
6 to 22% and 0% in the SDHD group. CgA identified one of three PET/CT-
7 visualised SDHB-related PGLs with normal plasma metanephrines at the 
8 expense of nine false positive results. A normal CgA demonstrated a negative 
9 predictive value of 92% for SDHB-related PGL. In patients with SDHB, plasma 
10 normetanephrine and metanephrine offered superior specificity (100%, p=0.01 
11 and 100%, p<0.01, respectively) with comparable sensitivity (67%, p=1.0 and 
12 11%, p=0.06, respectively) to CgA.
13
14 Conclusion 
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51 CgA does not provide additive benefit to standard surveillance for predicting the 
2 presence of SDHB- or SDHD-related PGL, but has a useful negative predictive 
3 value when normal in patients with SDHB mutation.
4
5 Key words: Chromogranin A; succinate dehydrogenase; SDHD; SDHB; 
6 paraganglioma; surveillance
7
8
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61 Introduction 
2 Paraganglioma (PGL) are rare neuroendocrine tumours that arise from 
3 autonomic ganglia and may either be functional, producing catecholamines, or 
4 non functional. Hereditary conditions predisposing to PGL are increasingly 
5 recognised and currently represent 25-30% of all PGL diagnoses.1 While 
6 sporadic PGL are rare, patients affected by hereditary PGL syndromes are at 
7 increased risk and may experience synchronous, metasynchronous or metastatic 
8 disease.1, 2 Loss of function mutations involving succinate dehydrogenase B 
9 (SDHB) and D (SDHD) result in an autosomal dominant increased risk of 
10 paraganglioma.1-3 
11
12 SDHB and SDHD have a highly penetrant phenotype, up to 50% and 80% 
13 lifetime risk, respectively.4-8 SDHB-related PGL are predominately derived from 
14 sympathetic ganglia of the thoracoabdominal region and are characterised by an 
15 aggressive disease course with malignant PGL over-represented.9-11 Due to 
16 maternal imprinting, SDHD-related disease only manifests when the mutation is 
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71 inherited paternally, and is characterised by non-malignant multifocal disease 
2 predominately involving parasympathetic ganglia of the head and neck.3, 4, 8 
3 Diagnosis of SDHx-related PGL can be delayed due to an increased frequency of 
4 biochemically silent and clinically asymptomatic phenotypes, potentially 
5 increasing the risk of malignant transformation.12 
6
7 The potential for early onset, aggressive and highly penetrant phenotypes 
8 necessitate lifelong surveillance as the standard of care for patients with SDHx 
9 mutation.13, 14 Surveillance protocols for SDHx-related disease continue to be 
10 refined.15 Current surveillance algorithms emphasise specialised imaging, such 
11 as magnetic resonance imaging/computed tomography, fluorodeoxyglucose 
12 (18F) positron emission tomography/computed tomography (18F-FDG PET/CT) 
13 or 68 Ga DOTATATE PET/computed tomography, and biochemistry, including 
14 plasma metanephrines.15-21 Challenges to this approach include the need for 
15 specialised testing and technical expertise, sometimes mandating significant 
Page 7 of 41
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81 travel time for patients, cost and radiation exposure across the lifespan. The 
2 relevance of interval biochemistry is uncertain.
3
4 Chromogranin A (CgA) is a major soluble protein in secretory dense core 
5 granules of neuroendocrine cells and cosecreted into serum with other stored 
6 peptides.22 Consequently, CgA is a widely available diagnostic biomarker for 
7 neuroendocrine tumours and is commonly used for surveillance of patients with 
8 SDHx mutations.23, 24 Recently CgA was demonstrated to have comparable and 
9 complementary diagnostic performance to plasma metanephrines, with a sensitivity of 
10 73.2% and specificity of 95.9%, in a SDHB and SDHD referral population with high 
11 prevalence of metastatic and multifocal disease under ideal diagnostic conditions.22 
12 However, the utility of CgA for PGL surveillance in unselected SDHx populations 
13 is controversial with false positive results a particular challenge.23, 25 False 
14 positive CgA results may occur due to proton pump inhibitor use (PPI), chronic 
15 kidney disease, heart failure or atrophic gastritis.23 We examined the diagnostic 
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91 value of CgA results in a population based sample of adults with SDHB and 
2 SDHD.
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10
1 Materials and methods
2 Tasmania is an island state in Australia with a single referral centre (the Royal 
3 Hobart Hospital) for patients with or at risk of endocrine neoplasia, including 
4 those with SDHB and SDHD mutations. As previously described,16 all adult 
5 patients with SDHB and SDHD mutations undergoing PGL surveillance with 18F-
6 FDG PET/CT and plasma metanephrines  at the Royal Hobart Hospital between 
7 1 July 2011 and 30 September PGL 2017 who had contemporary (within six 
8 months) assessment of CgA concentration were considered eligible for inclusion. 
9 Surveillance for PGL in asymptomatic adult SDHB and SDHD carriers at the 
10 Royal Hobart Hospital consists of annual biochemistry (plasma metanephrines 
11 and CgA) and second yearly imaging (four yearly neck and renal ultrasounds 
12 alternating with four yearly 18F-FDG PET/CT). The research program was 
13 approved by the Southern Tasmanian Health and Medical Human Research 
14 Ethics Committee (reference number H0014866).
15
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11
1 Patients were considered positive for a PGL-related abnormality if either 18F-
2 FDG PET/CT or plasma metanephrines were positive. PGL were considered 
3 functional when plasma metanephrines (metanephrines or normetanephrine) 
4 were elevated. CgA concentration was referenced against the result of PGL 
5 surveillance to determine the diagnostic value of CgA. CgA concentration was 
6 considered abnormal if it was greater than the upper limit of normal. Patient data 
7 was assessed in a cross-sectional manner to determine the ability of CgA 
8 concentration to predict the result of PGL surveillance. 
9
10 Plasma metanephrine measurement
11 Plasma metanephrines considered in this study included metanephrine and 
12 normetanephrine, but not 3-methoxytyramine. Plasma metanephrines were 
13 analysed using liquid chromatography–tandem mass spectrometry at the Clinical 
14 Pharmacology and Therapeutics laboratory, Austin Health. Briefly, following the 
15 addition of deuterated internal standard, solid phase extraction, dry down and 
16 reconstitution, samples were derivatised using cyanoborohydride and 
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12
1 acetaldehyde. Chromatography was performed using Agilent 1200 Infinity high 
2 performance liquid chromatography (Agilent Technologies, Mulgrave, Australia) 
3 and a reversed phase column (Atlantis T3 150 mm× 2.1 mm; 3 μm packing, 
4 Waters Australia) using a 0.2 mL/min flow of mobile phase delivering a linear 
5 acetonitrile gradient (4–24% over 5 min with 3 min re-equilibration) in 0.2% formic 
6 acid. Tandem mass spectrometric detection was performed using an Agilent 
7 6460 series instrument (Agilent Technologies, Australia). Electrospray ionization 
8 was used in positive ion mode at unit mass resolution and optimized detector 
9 settings for voltages, gas temperatures and flows.
10
11 Chromogranin A measurement
12 Patients were requested to fast prior to CgA assessment. All samples for CgA 
13 measurement were collected in a serum tube and placed in ice-water mixture to 
14 prevent breakdown of endogenous CgA. CgA was quantified using the DAKO 
15 (DAKO, Glostrup, Denmark) assay until 2014 (inter-assay coefficients of variation 
16 7% at a CgA concentration of 53 U/L, derived from 40 estimations). Subsequent 
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13
1 testing was done using the Cisbio (Cisbio Assay, Codolet, France) assay (inter-
2 assay coefficients of variation were 5.8% and 6.7% at a CgA concentration of 
3 20ug/L and 200ug/L, respectively, both derived from 30 estimations). Both assays 
4 used an ELISA format but different antibody specificity. The DAKO assay used 
5 two polyclonal antibodies with epitope specificity towards a 23 kD ‘C’ terminal 
6 fragment of CgA. The Cisbio assay used two monoclonal antibodies that had 
7 specificity directed to amino acid sequence 145 – 197 and 198 – 245. The 
8 reference range (<21.8 U/L) for the DAKO assay was derived from analysis of 
9 samples from 40 healthy volunteers. The reference range (27-94 μg/L) for the Cisbio 
10 assay was derived from analysis of samples from 60 healthy volunteers. Statistical 
11 correlation between assays was high (R2=0.99). Consistency of clinical interpretation of 
12 results between the two methods was also high (94%) with only two samples, both close 
13 to the assay cut offs, yielding different results between assays.  As the reference range 
14 for these assays differed, CgA concentration was expressed as multiples of the 
15 upper limit of normal (xULN, 21.8 U/L for the DAKO assay and 94 μg/L for the 
16 Cisbio assay). 
17
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14
1 Medical records and biochemistry were reviewed to determine PPI use, and the 
2 presence of chronic kidney disease (CKD, defined as an estimated glomerular 
3 filtration rate ≤ 60 mL/min/1.73m2),26 atrophic gastritis or heart failure. Patients 
4 were not excluded from analysis if these conditions were present, but their 
5 presence noted and impact assessed.
6
7 Data were collated and statistical analysis performed using GRAPHPAD PRISM 
8 Version 7.03 (GRAPHPAD Software Inc. La Jolla, CA, USA) and SigmaPlot 
9 Version 13 (Systat Software, San Jose, CA, USA). CgA was analysed as 
10 multiples of the upper limited of normal (xULN).  Students’ t-tests and Fisher 
11 exact tests were used to compare differences in means and proportions, 
12 respectively. Where data were not normally distributed, log transformations were 
13 performed. Where data failed to meet the equal variance test or Shapiro-Wilk 
14 normality test post log transformation, Mann-Whitney Rank Sum t-tests where 
15 used. McNemar’s t-test was used to compare the diagnostic performance of CgA 
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15
1 and plasma metanephrines. Statistical significance was defined as a two tailed p 
2 value ≤0.05.
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1 Results
2 There was no significant difference between patients with SDHB and those with 
3 SDHD with regard to age, sex or mean CgA concentration (Table 1). Patients 
4 with SDHB were significantly (p<0.001) less likely to have a PGL manifest at 
5 baseline compared to those with SDHD (17% vs 90%). When PGL was present, 
6 CgA was significantly higher (p=0.02) in patients with SDHB compared to those 
7 with SDHD (3.00±3.81 vs 0.80±0.55).  Patients with SDHB were more likely to 
8 have functional PGLs (p=0.03) and for these PGLs to affect the 
9 thoracoabdominal region (p=0.002). There was no significant difference between 
10 SDHB and SDHD patients with regard to the prevalence of malignant PGLs (33% 
11 vs 22%). Three patients with SDHB and two patients with SDHD had malignant 
12 PGLs with metastatic disease above and below the diaphragm in all cases.
13
14 Table 2 summarises the diagnostic performance of CgA concentration referenced 
15 against the outcome of PGL surveillance. CgA was significantly more likely to 
16 yield a concordant result for patients with SDHB compared to those with SDHD 
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1 (77% vs 22%, p=0.003). This was primarily due to normal CgA better predicting 
2 the absence of PGL in patients with SDHB versus SDHD (92% vs 0%, p<0.001), 
3 rather than a positive result predicting the presence of a PGL (40% vs 67%, 
4 p=0.56). In patients with SDHB, the sensitivity and specificity of CgA for 
5 abnormal surveillance results were 67% and 79%, respectively, compared to 
6 22% and 0% in patients with SDHD. The negative predictive value of a normal 
7 CgA concentration was 92% in patients with SDHB. Excluding all SDHB patients 
8 on proton pump inhibitors (n=6), with significant CKD (n=1), heart failure (n=0) or 
9 atrophic gastritis (n=0) from analysis regardless of the outcome of PGL 
10 surveillance yielded a sensitivity of 75% (35-97%) and specificity of 84% (69-
11 94%) in patients with SDHB. If plasma metanephrines were included in analysis 
12 and biochemistry defined as positive if either CgA or plasma metanephrines were 
13 elevated, then sensitivity increased to 78% (40-97%) and specificity to 80% (65-
14 91%). In the SDHB cohort, plasma normetanephrine had similar sensitivity 67% 
15 (30%-93%, p=1.0) but superior specificity 100% (91%-100%, p=0.01) compared 
16 to CgA for SDHB-related PGL (Figure 1B). Plasma metanephrine also had 
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1 superior specificity 100% (92-100%, p<0.01) with comparable sensitivity 11% (0-
2 48%, p=0.06) to CgA for SDHB-related PGL (Figure 1C). 
3
4 Patients with SDHB and a PGL were more likely to have an elevated CgA than 
5 SDHB patients without PGL (p=0.01, Figure 1A). CgA was also significantly 
6 higher (3.00±3.81xULN vs 0.89±1.17xULN, p=0.001) in patients with SDHB and 
7 PGL compared to SDHB patients without PGL. In patients with SDHD, CgA was 
8 not significantly different (p=0.33) between patients with and without PGL. CgA 
9 was more likely to be elevated in patients with a functional PGL compared to 
10 those with a non functional PGL (86% vs 18%, p=0.045). One patient with SDHB-
11 related PGL had elevated CgA without concurrent elevation of plasma 
12 metanephrines, however this PGL was also confirmed on concurrent 18F-FDG 
13 PET/CT imaging. One patient had elevated plasma metanephrines without 
14 elevation of CgA and two patients with normal CgA and plasma metanephrines 
15 had imaging-detected PGLs. 
16
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1 Discussion
2 In this population-based study, CgA had limited additive diagnostic value for 
3 predicting the presence of SDHx-related PGL, but offered potentially useful 
4 negative predictive value for patients with SDHB mutation. CgA demonstrated 
5 better diagnostic performance in SDHB-related compared to SDHD-related PGL 
6 surveillance. Corroborating existing literature,22 we found that CgA was (1) better 
7 able to predict the outcome of PGL surveillance in patients with SDHB compared 
8 to those with SDHD and (2) more likely to be elevated and significantly higher 
9 when PGL was present in patients with SDHB, but not in patients with SDHD. A 
10 normal CgA better predicted the absence of SDHB-related PGL with infrequent 
11 false negative results and a potentially useful negative predictive value. However, 
12 in our population-based SDHB cohort, CgA did not identify any PGLs that would 
13 not have been detected by routine surveillance, limiting its positive predictive 
14 utility in both SDHB- and SDHD-related PGL surveillance. 
15
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1 PGL related to SDHB and SDHD differ phenotypically. SDHD-related PGL 
2 preferentially arise from parasympathetic ganglia in the head and neck region 
3 whereas SDHB-related PGL more frequently arise from sympathetic ganglia and 
4 involve the thoracoabdominal region with a higher incidence of malignant 
5 disease.4, 7, 8 Our data reflect this anatomical divergence and support the growing 
6 body of literature suggesting that SDHB- and SDHD-related PGLs are 
7 biochemically divergent with CgA lacking diagnostic efficacy in patients with head 
8 and neck PGLs (exclusively SDHD patients in our cohort).24, 27 CgA was higher in 
9 patients with SDHB-related PGL compared to those with SDHD-related PGL. 
10 CgA was higher in patients with functional PGLs, possibly reflecting the 
11 necessary role of CgA in dense-core secretory granule biogenesis28 or 
12 cosecretion with catecholamines.29 The biochemical divergence between SDHB- 
13 and SDHD-related PGL potentially reflects the parasympathetic origin of head 
14 and neck predominant SDHD-related PGLs or may be attributable to other 
15 genotype-specific differences.27, 30 We were unable to differentiate these 
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1 possibilities due to the pronounced anatomical segregation by genotype in our 
2 cohort. 
3
4 Compared to a recent, highly controlled study in a SDHB referral population,27 
5 the sensitivity, specificity and ability of CgA to complement plasma metanephrine 
6 testing in our SDHB cohort was lower. This partially reflects the impact of PPI use 
7 and CKD in our cohort as exclusion of these participants increased sensitivity 
8 and specificity to the extent that the sensitivity of CgA was comparable, though 
9 specificity remained less than previously observed.27 The residual difference in 
10 specificity may be due to the lower prevalence of metastatic disease in our 
11 cohort. The complementary nature of CgA and plasma metanephrines for PGL 
12 diagnosis was also less apparent in our cohort. CgA was elevated in only one of 
13 three (33%) SDHB-related PGLs with normal plasma metanephrines, was less 
14 specific than plasma metanephrines alone and the sensitivity of CgA and plasma 
15 metanephrines together was only slightly higher than CgA alone. Thus in our 
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1 cohort, CgA was able to detect one additional PGL, which was concurrently 
2 visualised on 18F-FDG PET/CT, at the expense of nine false positive results. 
3
4 False positive results are a major limitation of CgA testing,23 but do not detract 
5 from the negative predictive value of a normal CgA result. In our SDHB cohort 
6 the negative predictive value of a normal CgA was 92%. Therefore, while a 
7 raised CgA is unlikely to meaningfully add to routine PGL surveillance, a normal 
8 CgA in a patient with SDHB mutation offers potentially informative negative 
9 predictive value as an ancillary test. These data should aid decision making in 
10 daily clinical practice, but are not sufficient to recommend CgA displace existing 
11 biochemical or imaging approaches to PGL surveillance. 
12
13 3-methoxytyramine is the O-methylated metabolite of dopamine and has emerged as a 
14 valuable biomarker of prevalent and metastatic SDHx-related PGL.31-33 Assessment of 3-
15 methoxytyramine is particular useful in head and neck PGL,34 which are less likely than 
16 abdominothoracic PGLs to be detected using metanephrine or normetanephrine.35 Given 
17 our data suggest that CgA offers limited positive predictive value to diagnostic 
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1 algorithms including 18F-FDG PET/CT and plasma metanephrines, it is 
2 conceivable that inclusion of 3-methoxytyramine in these algorithms will further 
3 supplant the role of CgA as a second line test.21
4
5 This study has potential limitations. Patients on PPIs and with mild renal 
6 dysfunction were included. This potentially underestimated the diagnostic 
7 performance of CgA due to false positive results, which we accounted by further 
8 analysis excluding relevant participants. The major benefit of this inclusive study 
9 design, combined with a population based sample from the only referral centre in 
10 an island state, is strong external validity and relevance to clinical practice. Our 
11 sample size was moderate, potentially limiting statistical analysis. However, in 
12 the context of an exceedingly rare disease, our sample size compares favourably 
13 and allowed comparisons between patients with SDHB and SDHD. Finally, two 
14 different assays were used to quantify CgA during the study period, potentially 
15 introducing additional variability. However, both the statistical correlation and 
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1 clinical consistency of assay results was high, suggesting that the overall impact 
2 of this change was limited. 
3
4 In conclusion, CgA does not meaningfully add to standard surveillance for 
5 predicting the presence of SDHB- or SDHD-related PGL, however it provides a 
6 potentially informative negative predictive value in patients with SDHB mutation.
7
8  
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1
2
Table 1. Characteristics of patients
SDHB
 (n=52)
SDHD 
(n=10)
p value
Age in years, mean ± SD 45.2 ± 15.7 48.3 ± 15.4 0.35
Female, n (%) 27 (52) 4 (40) 0.57
CgA, mean ± SD 1.35 ± 2.02 1.53 ± 2.35 0.99
PGL present, n (%) 9 (17) 9 (90) <0.01
      CgA, mean ± SD 3.00 ± 3.81 0.80 ± 0.55 0.02
  Component of testing positive, n (%)
      18F-FDG PET/CT 9 (100) 9 (100)
      Functional paraganglioma, n (%) 5 (55) 0 (00) 0.03
Malignant paraganglioma, n (%) 3 (33) 2 (22) 0.10
  Metastatic, n (%) 3 (100) 2 (100)
  Capsular invasion, n (%) 0 (0) 0 (0)
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Location of paraganglioma, n (%) <0.01
  Head and neck 0 (0) 6 (67)
  Thorax and abdomen 6 (67) 0 (0)
  Both or metastatic 3 (33) 3 (33)
1 Standard deviation (SD). Boldface denotes statistically significant result.
2 CgA is expressed as the multiple of upper limit of normal (xULN)
3 PGL present refers to the result of paraganglioma surveillance with 18F-
4 FDG PET/CT and plasma metanephrines (including metanephrine and 
5 normetanephrine) assessment. 
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1
Table 2. Diagnostic performance of CgA for predicting outcome of PGL 
surveillance
SDHB SDHD 
Diagnostic utility, result (95% CI)
 Sensitivity 0.67
(0.30-0.93)
0.22
(0.03-0.60)
 Specificity 0.79
(0.64-0.90)
0
(0.0-0.98)
 Positive predictive value 0.40
(0.24-0.58)
0.67
(0.38-0.87)
 Negative predictive value 0.92
(0.82-0.97)
0
 Positive likelihood ratio 3.2
(1.52-6.69)
0.20
(0.02-0.56)
 Negative likelihood ratio 0.42
(0.17-1.08)
-
2 Boldface denotes statistically significant result.
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1 Data expressed as result (95% confidence interval).
2 CI, confidence interval.
3
4
5
6
7
8 Figure 1A. 
9
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1
2
3 Figure 1B.
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1
2 Figure 1C. 
3
4 Figure 1 Legend. Spectrum of chromogranin A (CgA, Figure 1A) , 
5 normetanephrine (NMN, Figure 1B) and metanephrine (Figure 1C) results 
6 on a per patient basis stratified by SDHx and PGL status. Red symbols in 
7 Figure 1A denote functional PGLs (defined by elevated normetanephrine 
8 or metanephrine concentration). The dashed line represents the upper limit 
9 of normal. 
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1
2 Patients with SDHB and a PGL were more likely to have an elevated CgA. CgA 
3 was more likely to be elevated in patients with a functional PGL compared to 
4 those with a non functional PGL (Figure 1A). Plasma normetanephrine and 
5 metanephrine had similar sensitivity but superior specificity compared to CgA for 
6 SDHB-related PGL (Figures 1B and 1C). 
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